Purification and Characterization of a Cytosolic Ca^{2+} -Independent Phospholipase A_2 from Bovine Brain

Eui Man Jeong, Kyong Hoon Ahn, Hyung Jin Jeon, Ha Dong Kim, Ho Sup Lee, Sung Yun Jung, Kwang Mook Jung, Seok Kyun Kim, Joseph V. Bonventre¹, and Dae Kyong Kim*

The Ca^{2+} -independent phospholipase A_2 (iPLA₂) subfamily of enzymes is associated with arachidonic acid (AA) release and the subsequent increase in fatty acid turnover. This phenomenon occurs not only during apoptosis but also during inflammation and lymphocyte proliferation. In this study, we purified and characterized a novel type of iPLA₂ from bovine brain. iPLA₂ was purified 4,174-fold from the bovine brain by a sequential process involving DEAE-cellulose anion exchange, phenyl-5PW hydrophobic interaction, heparin-Sepharose affinity, Sephacryl S-300 gel filtration, Mono S cation exchange, Mono Q anion exchange, and Superose 12 gel filtration. A single peak of iPLA₂ activity was eluted at an apparent molecular mass of 155 kDa during the final Superose 12 gel-filtration step. The purified enzyme had an isoelectric point of 5.3 on two-dimensional gel electrophoresis (2-DE) and was inhibited by arachidonyl trifluoromethyl ketone (AACOCF₃), Triton X-100, iron, and Ca^{2+} . However, it was not inhibited by bromoenol lactone (BEL), an inhibitor of iPLA₂, and adenosine triphosphate (ATP). The spot with the iPLA₂ activity did not match with any known protein sequence, as determined by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) analysis. Altogether, these data suggest that the purified enzyme is a novel form of cytosolic iPLA₂.

INTRODUCTION

Phospholipase A_2 (phosphatide 2-acylhydrolase; PLA₂; EC 3.1.1.4) hydrolyzes the *sn*-2 position of phospholipids to release free fatty acids and lysophospholipids, which are important precursors of bioactive substances including prostaglandins, leukotrienes, lysophosphatidic acid, and platelet-activating factor (PAF) (Schaloske and Dennis, 2006). The PLA₂ family is largely divided on the basis of Ca^{2+} requirement and cellular localization into 3 major subfamilies: the secretory PLA₂ (sPLA₂), cytosolic PLA₂ (cPLA₂), and Ca^{2+} -independent PLA₂ (iPLA₂). sPLA₂ subfamily are stored in cytosolic granules or synthesized

upon stimulation and then secreted extracellularly, whereas cPLA₂ and iPLA₂ subfamilies comprise intracellular enzymes. To date, this growing family of lipases has been categorized into 12 groups. Groups IIA, IVA, V, and VI have been extensively studied in the central nervous system (Green et al., 2008; Sun et al., 2010). Group VI iPLA₂, which does not require Ca^{2+} for catalysis, was purified and cloned in 1996. However, this enzyme was purified from rat brain homogenates by using multiple column chromatographic procedures with a very low yield (Molloy et al., 1998). Reportedly, this enzyme exists in aggregates and occurs in several splice variants (Larsson et al., 1998; Tang et al., 1997). Therefore, a wide variety of iPLA₂ activities has been found in different tissues (Tang et al., 1997).

Increased PLA₂ activity and the resultant excessive production of pro-inflammatory lipid mediators potentially lead to neurological disorders, such as ischemia (Bonventre et al., 1997; Tabuchi et al., 2003), Alzheimer's disease (Farooqui et al., 1997; 2006; Stephenson et al., 1996), spinal cord injury (Anderson et al., 1985; Lukacova et al., 1996), Parkinson's disease (Klivenyi et al., 1998; Tariq et al., 2001; Yoshinaga et al., 2000), schizophrenia (Junqueira et al., 2004; Ross et al., 1997; 1999; Yao et al., 2000), and multiple sclerosis (Kalyvas and David, 2004; Kalyvas et al., 2009; Pinto et al., 2003). Besides, lysophosphatidylcholine, a product of PLA₂, leads to demyelination (Dousset et al., 1995). In the brain, the basal expression and activity of iPLA₂ are higher than those of cPLA₂ or sPLA₂ (Farooqui et al., 1999; Molloy et al., 1998). Therefore, inhibition of iPLA₂ activity is an attractive approach for designing novel drugs to treat neurodegenerative disease-associated inflammation. However, until now, enzymes of the iPLA₂ subfamily have not been fully characterized and identified in nerve tissues. Therefore, identifying a form of PLA₂ in nerve tissues is essential to better understand and efficiently treat neurodegenerative diseases.

In this study, we purified a cytosolic iPLA₂ from bovine brain homogenates by using serial column chromatography. We classified this enzyme as a novel form of iPLA₂ on the basis of biochemical studies. It had an apparent molecular mass of 155 kDa and an isoelectric point of 5.3 on two-dimensional gel elec-

Department of Environmental and Health Chemistry, College of Pharmacy, Chung-Ang University, Seoul 156-756, Korea, ¹Medical Services, Brigham and Women's Hospital, Harvard Medical School, Boston, Longwood, MA, USA

*Correspondence: kimdk@cau.ac.kr

trophoresis (2-DE). In addition, the purified iPLA₂ functioned at an optimal pH of 9.5 and its activity was inhibited by arachidonyl trifluoromethyl ketone (AACOCF₃), Triton X-100, iron ions, and millimolar concentrations of Ca²⁺. This enzyme differed from the previously reported types of iPLA₂ from other tissues (Ackermann et al., 1994; 1995; Hazen and Gross, 1991; Hazen et al., 1990; Wolf and Gross, 1985) in that it was not inhibited by bromoenol lactone (BEL) and adenosine triphosphate (ATP). We expect this novel enzyme to play a crucial role in the production of eicosanoids.

MATERIALS AND METHODS

Materials

1-stearoyl-2-[1-¹⁴C] arachidonoyl-*sn*-glycero-3-phosphocholine (2-[1-¹⁴C]AA-GPC; 55.3 mCi/mmol), 1-acyl-2-[1-¹⁴C]arachidonoyl-*sn*-glycero-3-phosphoethanolamine (2-[1-¹⁴C]AA-GPE; 55.1 mCi/mmol), and 1-palmitoyl-2-[1-¹⁴C]palmitoyl-*sn*-glycero-3-phosphocholine (2-[1-¹⁴C]PA-GPC; 55.6 mCi/mmol) were purchased from Amersham Biosciences (Buckinghamshire, UK). Adenosine 5'-triphosphate disodium salt and Triton X-100 were purchased from Sigma-Aldrich (USA). Heparin-Sepharose CL-6B gels, Mono Q anion-exchange columns, Mono S cation-exchange columns, and Superose 12 fast protein liquid chromatography (FPLC) gel-filtration columns were purchased from Pharmacia LKB Biotechnology (Sweden). DE52 gel was purchased from Whatman (UK). A phenyl-5PW hydrophobic column was purchased from Tosoh (Japan). Bovine brain tissue was obtained from a local slaughterhouse in Seoul and stored in a -70°C deep freezer. Immobilized DryStrip (pH 4-7, 7 cm), 2-DE reagents, including the IPGphor for first-dimension separation, and the silver staining reagent kit were purchased from Amersham Pharmacia Biotech (Sweden). Second-dimension separation was performed in a Mini Protein System from Bio-Rad (USA).

iPLA₂ activity assay

The substrate, 2-[1-¹⁴C]AA-GPC, was dried under nitrogen stream and subsequently resuspended in ethanol. The iPLA₂ activity assay was performed in 100 µl of the standard reaction buffer [200 mM Tris-HCl (pH 7.5) and 5 mM EDTA] containing iPLA₂ preparations and 0.45 nmol of the substrate (~55,000 cpm). Crude or purified iPLA₂ samples were incubated with the substrate at 37°C for 15-30 min. The assay was subsequently terminated by adding 560 µl of modified Dole's reagent (*n*-heptane/isopropyl alcohol/1 N H₂SO₄ as 400/190/10 [v/v/v]) and 110 µl of water, vortex mixing, and centrifuging. Then, 150 µl of the upper phase were transferred to a new microtube, to which 800 µl of *n*-heptane and silica gel (~5 mg) was added. The sample was vortex-mixed and centrifuged again. An aliquot (800 µl) of the supernatant was removed and added to 2.5 ml of β-scintillation solution (Insta Gel-XF) and counted for radioactivity with a Packard Tri-Carb liquid scintillation counter (Packard Instrument Co., USA). To investigate the optimal pH for iPLA₂ activity, the following buffers were prepared: 200 mM Tris-HCl (pH 7.5-8.5) and 200 mM glycine-NaOH (pH 9.0-10.5). The optimal pH for iPLA₂ activity was 9.5, but the assay was conducted at pH 7.5 to perform the experiments under physiological conditions. At this pH, iPLA₂ activity was 5.7-fold less than that at pH 9.5.

Preparation of enzyme extracts from bovine brain tissues

Frozen bovine brain tissues (1.2 kg) were cut into small pieces and homogenized with 5 volumes of homogenizing buffer (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, 3 mM MgCl₂, 50 mM KCl,

and 10 mM 2-mercaptoethanol). The homogenates were centrifuged at 10,000 × *g* at 4°C for 10 min to remove the cell debris. Subsequently, the supernatants were centrifuged at 10,000 × *g* at 4°C for 1 h, and the pH of the resulting supernatants (S10) was adjusted to pH 5.0 with acetic acid (1:1 dilution in distilled water). These supernatants were again centrifuged at 10,000 × *g* at 4°C for 15 min. The precipitates (P10; pH 5.0) were resuspended in 25 mM Tris (pH 7.5), 1 mM EDTA, and 10 mM 2-mercaptoethanol, and then applied to a DEAE-cellulose anion-exchange column.

Purification of iPLA₂

The resuspension (P10; pH 5.0) was loaded onto a DEAE-cellulose anion-exchange column (DE52; 2.5 × 12.5 cm, 400 ml of bed volume) pre-equilibrated with buffer A (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, and 10 mM 2-mercaptoethanol) by a peristaltic pump (Eyela, Japan) at a flow rate of 2 ml/min. After the column was washed with buffer A, the washed gel was eluted stepwise with buffer A containing 1.0 M NaCl. Thirty milliliters of the eluate were collected per fraction. Aliquots of each fraction were used for measurement of the iPLA₂ activity. The active fraction was pooled. The final KCl concentration was adjusted to 2 M KCl by adding KCl powder and mixing for 2 h at 4°C. The resultant pool was centrifuged at 100,000 × *g* for 1 h at 4°C. The supernatants were applied to a Phenyl-5PW hydrophobic column (21.3 mm × 15 cm) pre-equilibrated with 25 mM Tris (pH 7.5) buffer containing 1 mM EDTA, 10 mM 2-mercaptoethanol, and 1.0 M NaCl. The column was washed with the same buffer and then eluted at a flow rate of 5 ml/min with 150 ml of the same buffer in a linear gradient of buffer B [25 mM glycine-NaOH (pH 9.0), 1 mM EDTA, and 10 mM 2-mercaptoethanol]. Five milliliters of the eluate were collected per fraction. The active fraction was again pooled and the pH was adjusted to pH 6.2 with acetic acid (1:30 dilution in distilled water). The obtained solution was applied to a heparin-Sepharose CL-6B column (5 ml) pre-equilibrated with buffer S [50 mM CH₃COONa (pH 5.6), 1 mM EDTA, and 10 mM 2-mercaptoethanol]. After washing with buffer S, the protein bound to the column was eluted with a linear gradient of buffer A containing 1.0 M NaCl. Three milliliters of the eluate were collected per fraction. The fractions with iPLA₂ activity were pooled and concentrated to ~7 ml by using 20-ml Centricon (Vivascience, UK) and applied to a Sephacryl S-300 gel-filtration column (26 mm × 60 cm) pre-equilibrated with buffer A containing 0.1 M NaCl. The protein bound to the column was eluted with buffer A containing 0.1 M NaCl at a flow rate of 1 ml/min. Five milliliters of the eluate were collected per fraction. The fractions with iPLA₂ activity were pooled and applied to a Mono S cation-exchange FPLC column (5.0 mm × 5.0 cm) pre-equilibrated with buffer S. After washing with buffer S, the protein was eluted with a linear gradient of buffer A containing 1.0 M NaCl at a flow rate of 1 ml/min. One milliliter of the eluate was collected per fraction. The fractions with iPLA₂ activity were pooled, diluted with buffer Q [25 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 10 mM 2-mercaptoethanol], and applied to a Mono Q anion-exchange FPLC column (5.0 mm × 5.0 cm) pre-equilibrated with buffer Q. After washing with buffer Q, the protein was eluted at a flow rate of 1 ml/min with 20 ml of the buffer Q in a gradient of 0.0-1.0 M NaCl. The fractions containing iPLA₂ activity were pooled and concentrated to ~200 µl by using 4-ml Centricon (Vivascience) and applied to a Superose 12 FPLC gel-filtration column pre-equilibrated with buffer A containing 0.1 M NaCl. The protein was eluted with the buffer A containing 0.1 M NaCl at a flow rate of 0.5 ml/min. Five-hundred microliters of the eluate was collected per fraction. To estimate the apparent molecular

weight of iPLA₂, β -amylase (200,000 Da), alcohol dehydrogenase (150,000 Da), bovine serum albumin (BSA; 66,000 Da), carbonic anhydrase (29,000 Da), and cytochrome *c* (12,400 Da) were used as standards and applied under the same experimental conditions.

Protein quantification and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)

To monitor the amount of protein present during the process of iPLA₂ purification, absorbance was measured at 280 nm by using an ultraviolet (UV) spectrophotometer. The protein concentration in each sample was determined by Bradford method (Bio-Rad). Enzymatic purity was monitored by SDS-PAGE on 8% gels, as described by Laemmli (1970). The gels were stained by silver staining.

2-DE

The active fractions obtained by Superose 12 FPLC gel-filtration chromatography were changed to a rehydration solution containing 7 M urea, 2 M thiourea, 4% CHAPS, 40 mM Tris, 0.002% bromophenol blue (BPB), 100 mM dithiothreitol, and 0.5% Phamalyte (pH 4-7; Amersham Pharmacia Biotech) by using 4-ml Centricon (Vivascience). The dry strips (pH 4-7, non linear, 7 cm of length; Amersham Pharmacia Biotech) were rehydrated with 125 μ l of the sample solution for 12 h at 20°C. Electrofocusing of rehydrated gels was carried out by using the following running conditions: 100 μ l per strip at 20°C; 150 V for 1 h (step and hold), 500 V for 1 h (step and hold), 1,000 V for 2 h (step and hold), and 8,000 V for 4 h (step and hold). The electrofocused strips were equilibrated by using an equilibration buffer containing 6 M urea, 2% (w/v) SDS, 0.375 M Tris-HCl gel buffer (pH 8.8), 2.5% (w/v) acrylamide solution, 20% glycerol, 5 mM tributylphosphine, and a trace amount of BPB for 30 min at room temperature with gently shaking. The equilibrated strips were loaded onto 8% SDS-PAGE gels for separation by size. The strips were embedded with melted 0.5% (w/v) agarose before loading onto the SDS-PAGE gels. Separated proteins were visualized by using a mass spectrometry (MS)-compatible silver staining kit (PlusOne; Amersham Pharmacia Biotech).

Protein identification by peptide mass fingerprinting analysis

Peptide mass fingerprinting analysis was performed as described previously (Scheler et al., 1998). In brief, the 155-kDa spot was stained with silver nitrate, excised from the 2-DE gel, and digested with trypsin. An aliquot of the total digest was used for peptide mass fingerprinting. Masses were measured with a Bruker Reflex IV mass spectrometer (Bruker Daltonik, Germany), equipped with a 337-nm nitrogen laser and operated in positive ion reflector mode. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) analysis was performed using α -cyano-4-hydroxycinnamic acid as the matrix. Spectra were acquired over 750-3000 m/z and calibrated externally using the peptide calibration standard (Bruker Daltonik). Delayed ion extraction resulted in peptide masses with less than 50 ppm of mass accuracy on an average. Proteins were identified by peptide mass fingerprinting with the search engine programs ProFound and Mascot.

Statistical analysis

Data are presented as mean values $\pm$ standard deviation (SD) of the indicated number of experiments. One-way ANOVA or Student's *t*-test was used for statistical analysis. *P* < 0.05 was considered statistically significant.

RESULTS

Purification of iPLA₂ from bovine brain

To detect iPLA₂ activity in brain, we utilized bovine brain homogenates and traced the enzyme activity in Tris buffer containing 5 mM EDTA. Initially, to remove most contaminant proteins before proceeding to column chromatography, we used an isoelectric point precipitation method. When we precipitated the proteins present in the S10 supernatants under various pH ranges, we could maximally recover 71.8% of the total iPLA₂ activity in pH 5.0 precipitates, suggesting that brain-derived iPLA₂ may have a pI value of ~5.0. iPLA₂ was then purified from the pH 5.0 precipitates (P10) by the sequential process of anion exchange, hydrophobic interaction, heparin affinity, size exclusion, cation-exchange FPLC, anion-exchange FPLC, and gel-filtration FPLC. First, P10 were applied to a DE52 anion-exchange column. This step did not yield a high purification factor (1.3-fold), but many redundant proteins were eliminated in the pass-through fractions (Fig. 1A, Table 1). Next, the active fractions were salted out by the addition of a 2 M KCl solution and mixed for 2 h at 4°C, after which the pool was centrifuged at 100,000 $\times g$ for 1 h at 4°C. The resulting supernatant, which was free from larger amount of contaminants but retained the full iPLA₂ activity, was applied to a Phenyl-5PW hydrophobic column (Fig. 1B). At this step, although only 10% of the total applied iPLA₂ activity could be recovered in the active fractions of the eluate, the iPLA₂ activity-containing fraction was eluted as a single peak slightly earlier than the main protein peak. Therefore, the specific activity was drastically increased from 0.012 to 0.349 nmol $\cdot$ min⁻¹ $\cdot$ mg⁻¹ (Table 1). A pool of the active fractions was subsequently applied to a heparin-Sepharose affinity column (Fig. 1C). The proteins were eluted at two major protein peaks, but iPLA₂ activity was obtained as ~65% of the total applied activity in earlier fractions than the main protein peaks. Therefore, this step was also effective for iPLA₂ purification. Next, the active fractions of the heparin-Sepharose column were concentrated to ~2 ml and applied to a Sephacryl S-300 gel-filtration column (Fig. 1D). Although the majority of the proteins were eluted in void volume with no activity, 73% of the loaded iPLA₂ activity was recovered in a single active peak at ~160 kDa when we estimated the molecular mass by applying standard proteins under the same conditions (data not shown). Therefore, this step raised the specific activity by ~3-fold. The Sephacryl S-300 active fractions were pooled and applied to a Mono S FPLC column (Fig. 1E). At this step, the proteins were separated as two major peaks, with 88% of the applied iPLA₂ activity being eluted in the smallest one. Then, the active fractions of the Mono S column were pooled and loaded to a Mono Q FPLC column (Fig. 1F). This step resulted in a slight increase in the specific activity. Besides, we could reduce the volume of the active eluate from 13 ml to 5 ml. The active fractions obtained from the Mono Q column were further concentrated to ~200 μ l and injected into a Superose 12 gel-filtration column (Fig. 1G). At this step, the total activity dropped to 20%, probably because of the concentration step in which proteins might be denatured and lose their activity, but the specific activity increased by 3.15-fold. As shown in the inset of Fig. 1G, iPLA₂ activity was observed as a single peak with an estimated molecular mass of ~160 kDa. The chromatographic processes resulted in a 4,174-fold purification of iPLA₂ and yielded ~0.11% of the S10 fraction, as summarized in Table 1.

MALDI-TOF analysis of the brain-derived iPLA₂

To identify the purified iPLA₂ form, we separated proteins of the active fractions from the final purification step by SDS-PAGE

Fig. 1. Column chromatography profiles of iPLA₂ from bovine brain. iPLA₂ was prepared from bovine brain homogenates by precipitation at pH 5.0 with acetic acid followed by a series of chromatography steps. DEAE-cellulose anion-exchange chromatography (A), Phenyl-5PW hydrophobic chromatography (B), heparin-Sepharose CL-6B affinity chromatography (C), Sephacryl S-300 gel-filtration chromatography (D), Mono S cation-exchange FPLC (E), Mono Q anion-exchange FPLC (F), and Superose 12 FPLC (G). The inset in (G) shows the calibration curve for estimation the apparent molecular mass of iPLA₂. Molecular mass standard proteins were β -amylase (200 kDa), alcohol dehydrogenase (150 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), and cytochrome *c* (12 kDa). Data is representative of at least ten independent experiments.

Table 1. Purification of a cytosolic iPLA₂ from the bovine brain

Step	Protein (mg)	Total activity (nmol/min)	Specific activity (nmol/min/mg)	Purification (fold)	Yield (%)
S10	36,000	74.6	0.002	1.0	100
pH 5.0-extract	5,750	53.6	0.009	4.5	71.8
DE 52	1,386	16.7	0.012	5.9	22.4
Phenyl-5PW	5	1.7	0.349	169.8	2.34
Heparin-Sepharose	2.3	1.1	0.48	229.3	1.42
Sephacryl S-300	0.5	0.8	1.61	780.6	1.08
Mono S	0.26	0.7	2.71	1,320	0.95
Mono Q	0.20	0.5	2.72	1,325	0.73
Superose 12	0.01	0.1	8.58	4,174	0.11

Data is representative of at least ten independent experiments.

Fig. 2. Superose 12 FPLC of iPLA₂ from the active eluate obtained from Mono Q FPLC. Equal volumes of the fractions from the Superose 12 FPLC were assayed for iPLA₂ activity, and separated by SDS-PAGE, and visualized by silver staining, as described in the "Materials and Methods". These data are representative of at least five independent experiments.

(Fig. 2). Several proteins were observed. The enzymatic activity paralleled the intensity of the 155- and 175-kDa bands, in close agreement with the apparent molecular mass determined by Superose 12 gel-filtration (Fig. 1G). The proteins were further evaluated by 2-DE. The same samples were electrofocused on IPG dry strips (pH 4-7, nonlinear) and separated by SDS-PAGE (Fig. 3). The 155- and 175-kDa bands were each separated into two spots. Whereas the intensities of the two spots at 175 kDa and of one spot at 155 kDa did not correlate with the enzymatic activity, the spot at 155 kDa (which we named "spot A") correlated well. The identification of 155-kDa iPLA₂, separated by 2-DE SDS-PAGE, was achieved by peptide mass fingerprint using MALDI-TOF MS. MALDI-TOF MS analysis of the purified enzyme revealed no homology to any known protein (data not shown).

Characterization of the purified iPLA₂

To characterize the purified iPLA₂, the active fractions obtained from the final Superose 12 gel-filtration column step were used. First, we examined Ca²⁺ dependency. The activity was not induced by Ca²⁺ addition, but instead significantly decreased at millimolar concentrations of Ca²⁺ (Fig. 4A). We then examined the effects of several metal ions on the iPLA₂ activity, including Fe²⁺, Fe³⁺, Zn²⁺, Cu²⁺, Mg²⁺, and Mn²⁺ (Fig. 4B). The enzymatic activity was reduced to less than 15% at 0.1 mM of Fe²⁺ or Fe³⁺ and less than 40% at 0.5 mM of Mn²⁺. However, similar concentrations of Cu²⁺ and Mg²⁺ had little effect on iPLA₂ activity.

To determine substrate preference, iPLA₂ activity was assayed by analyzing the reaction products by thin layer chromatography using various phospholipids as described previously (Kim and Bonventre, 1993). We found iPLA₂ activity that preferred 2-[1-¹⁴C]AA-GPC and 2-[1-¹⁴C]AA-GPE by 28- and 81-fold, respectively, to 2-[1-¹⁴C]PA-GPC (Table 2). These data suggested the high selectivity of iPLA₂ for phospholipids containing arachidonic acid (AA).

We examined the effect of pH on iPLA₂ activity. iPLA₂ had optimal activity at an alkaline pH (Fig. 4C). This pH profile seems to be unique; enzymes of group IV and group VI PLA₂ are known to have optimal activity at pH 7.5 (Hiraoka et al., 2002), and group XV lysosomal PLA₂ has optimal activity at pH 4.5 (Hiraoka et al., 2002), suggesting that this brain-derived type of iPLA₂ may be different from other iPLA₂ types. Next, we examined the effect of PLA₂ inhibitors on the iPLA₂ activity (Fig. 4D). The activity was not decreased by 100 μM of BEL, a selective inhibitor of group VI Ca²⁺-independent PLA₂s with IC₅₀ of 0.5-5.0 μM (Hooks and Cummings, 2008), but was significantly inhibited by 10 μM of AACOCF₃, which is known to inhibit enzymes of group IV and group VI PLA₂ with IC₅₀ of 1.5 and 6.0 μM, respectively (Farooqui et al., 2006; Riendeau et al., 1994). In addition, the purified iPLA₂ activity was not significantly influenced by ATP (Fig. 4E), which is known to stabilize and activate group VI PLA₂ (Lio and Dennis, 1998). On the other hand, Triton X-100 is required to form micelles that allow the enzyme to be efficiently accessible to the substrate. Therefore, Triton X-100 should be added to the assay buffer at a concentration of at least 400 μM to favor the activities of enzymes of group IV and group VI PLA₂ (Lucas and Dennis, 2005). However, unexpectedly, the purified iPLA₂ activity was very sensitive to Triton X-100; the activity was almost completely inhibited even in the presence of 0.01% Triton X-100 (~170 μM; Fig. 4E). These data suggested that this brain-derived form of iPLA₂ might be distinct from enzymes of group IV and group VI PLA₂.

Fig. 3. 2-DE analysis of Superose 12 FPLC fractions. The fractions [20 (A), 21 (B), 22 (C), and 25 (D)] obtained from Superose 12 FPLC were analyzed by 2-DE, as described in the "Materials and Methods". The positions of external marker proteins are shown on the left side of the gels. The encircled areas indicate spot A.

Table 2. Substrate preference of the purified iPLA₂

Substrate	Activity (nmol/min/mg)
2-[1- ¹⁴ C]AA-GPE	24.2
2-[1- ¹⁴ C]AA-GPC	8.5
2-[1- ¹⁴ C]PA-GPC	0.3

The active fraction obtained from the Superose 12 gel-filtration column was assayed with the indicated phospholipids using standard assay conditions.

DISCUSSION

The activation of PLA₂ boosts the inflammatory response by catalyzing the release of AA and subsequent production of its metabolites, including prostaglandins and leukotrienes. Because the lipid metabolites mediate many neurodegenerative diseases including cerebral ischemia, Alzheimer's disease, and neuronal injury (Takemiya et al., 2007), PLA₂ is considered to play important pathophysiological roles in the nervous system (Shinzawa et al., 2008; Strokina et al., 2007; Sun et al., 2004). Therefore, identifying a form of PLA₂ specific to nervous tissues would be of great importance for understanding neurodegenerative diseases and developing efficient therapies.

In the present study, we purified a form of iPLA₂ from the bovine brain by using sequential column chromatographic steps. We found that this iPLA₂ has several unique biochemical properties when compared with the previously reported forms of iPLA₂, including group IVC cytosolic, group VI Ca²⁺-independent, and group XV lysosomal PLA₂ forms, and group VII and

group VIII PAF acetylhydrolases (Burke and Dennis, 2009). First, the purified iPLA₂ was insensitive to micromolar concentrations of Ca²⁺ but was inhibited by millimolar concentrations of Ca²⁺ (Fig. 4A). Interestingly, the enzymatic activity was also almost completely inhibited by millimolar concentrations of Fe²⁺, Fe³⁺, and Zn²⁺ and was reduced to ~40% by 0.5 mM of Mn²⁺ but was unaffected by Mg²⁺ or Cu²⁺ (Fig. 4B). Second, the enzyme was purified without any detergent. Enzymes of group IVC and group VI PLA₂ reportedly require 400–500 μM of Triton X-100 for optimal activity (Lucas and Dennis, 2005). However, this iPLA₂ was completely inhibited even in the presence of 0.01% Triton X-100 (~170 μM; Fig. 4E). It is difficult to distinguish between the effect of Triton X-100 on the enzyme and a structural conformation of the substrate. However, considering the sensitivity of the inhibitory effect, we hypothesize that Triton X-100 might mask a lipophilic active site, as in the case of the mammalian NADH-ubiquinone oxidoreductase (Ushakova et al., 1999). Third, the enzymatic activity-containing fraction was eluted as a peak at a molecular mass of ~160 kDa with a Superose 12 FPLC gel-filtration column (Fig. 1G). Although several protein bands were separated by SDS-PAGE, the intensity of the bands corresponding to 155- and 175-kDa proteins paralleled the enzymatic activity (Fig. 2). When the proteins were further separated by 2-DE, two spots at 175 kDa and one spot at 155 kDa were not correlated with the enzyme activity. However, we found that the enzyme activity was well correlated with the spot at 155 kDa, which we named "spot A" (Fig. 3). Some reports have suggested that the high apparent molecular mass of some iPLA₂ forms is due to their association with other proteins (Ackermann et al., 1994; Larsson et al., 1998; Ramanad-

Fig. 4. Characterization of the purified iPLA₂. Purified iPLA₂ was pre-incubated with the indicated concentrations of Ca²⁺ (A) or metal ions (B) for 10 min at 37°C and then incubated with 2-[1-¹⁴C]AA-GPC for 30 min at 37°C. Each data point represents the mean ± SD of at least five independent experiments. (C) The purified iPLA₂ activity was assayed in buffers at pH 4-11 by incubation with 2-[1-¹⁴C]AA-GPC for 30 min at 37°C. Each data point represents the mean ± SD of at least three independent experiments. (D) Purified iPLA₂ was pre-incubated with the indicated concentration of BEL or AACOCF₃ for 10 min at 37°C, followed by incubation with 2-[1-¹⁴C]AA-GPC for 30 min. (E) Purified iPLA₂ was pre-incubated with the indicated concentrations of ATP and Triton X-100 for 10 min at 37°C, and then incubated with 2-[1-¹⁴C]AA-GPC for 30 min at 37°C. Statistical significance was assessed by one-way ANOVA in (A, C, and E) and Student's *t*-test in (D). *** *P* < 0.001; ** *P* < 0.01.

ham et al., 1996). However, our purified 155-kDa iPLA₂ did not form aggregates with other proteins, because PLA₂ activity was obtained as a single peak at a molecular mass of ~160 kDa from the Superose 12 FPLC gel-filtration column.

Fourth, the purified iPLA₂ activity was inhibited by AACOCF₃, which is also known to inhibit group IV PLA₂ through a slow- and tight-binding mechanism (Street et al., 1993; Trimble et al., 1993). However, the enzymatic activity was not influenced by BEL (Fig. 4D), which is known to specifically inhibit group VI PLA₂ activity as a mechanism-based suicidal inhibitor (Hooks and Cummings, 2008). Fifth, ATP, which seems to bind and stabilize group VIA PLA₂ (Lio and Dennis, 1998), had no influence on the brain-derived iPLA₂ activity (Fig. 4E). Sixth, the purified brain form of iPLA₂ exhibited head group preference for ethanolamine rather than for choline as the substrate. In addition, it showed remarkable selectivity toward phospholipids containing AA at the *sn*-2 position (Table 2). This substrate preference of the purified enzyme is different from the previ-

ously identified PLA₂ forms. For instance, enzymes of group IVC and group VI PLA₂ show very little specificity for AA-containing phospholipids (Burke and Dennis, 2009; Pickard et al., 1999); group VII and group VIII PAF acetylhydrolases primarily remove the acetyl group from the *sn*-2 position of PAF; group XV lysosomal PLA₂ seems to preferentially have the activity of 1-*O*-acylceramide synthase rather than PLA₂ (Hiraoka et al., 2002). Finally, group XV lysosomal PLA₂ has optimal activity at pH 4.5 (Hiraoka et al., 2002), but the purified iPLA₂ was optimally activated at pH 9.5 (Fig. 4C).

In summary, we purified a novel form of iPLA₂ from cytosolic fractions of the bovine brain by using acidic pH precipitation and sequential column chromatographic methods with ~0.11% yield and 4,174-fold purification. This enzyme has several different biochemical characteristics from the previously identified iPLA₂ forms, including insensitivity to BEL and ATP, complete inactivation by Triton X-100, and pH dependency. The protein spot with iPLA₂ activity did not match any annotated protein se-

quence, as determined by 2-DE and MALDI-TOF. Given these data, the purified enzyme is a novel type of cytosolic iPLA₂. In the future, the primary structure of this novel enzyme should be resolved and its underlying molecular mechanisms comprehended. Such knowledge would provide insight into the pathophysiology of neuronal disease.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea Grant funded by the Korean Government (MEST) (NRF-2010-0020844).

REFERENCES

- Ackermann, E.J., Kempner, E.S., and Dennis, E.A. (1994). Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization. *J. Biol. Chem.* **269**, 9227-9233.
- Ackermann, E.J., Conde-Frieboes, K., and Dennis, E.A. (1995). Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. *J. Biol. Chem.* **270**, 445-450.
- Anderson, D.K., Saunders, R.D., Demediuk, P., Dugan, L.L., Braughler, J.M., Hall, E.D., Means, E.D., and Horrocks, L.A. (1985). Lipid hydrolysis and peroxidation in injured spinal cord: partial protection with methylprednisolone or vitamin E and selenium. *Cent. Nerv. Syst. Trauma* **2**, 257-267.
- Bonventre, J.V., Huang, Z., Taheri, M.R., O'Leary, E., Li, E., Moskowitz, M.A., and Sapirstein, A. (1997). Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A2. *Nature* **390**, 622-625.
- Burke, J.E., and Dennis, E.A. (2009). Phospholipase A2 biochemistry. *Cardiovasc. Drugs Ther.* **23**, 49-59.
- Dousset, V., Brochet, B., Vital, A., Gross, C., Benazzouz, A., Boulle, A., Bidabe, A.M., Gin, A.M., and Caille, J.M. (1995). Lysolecithin-induced demyelination in primates: preliminary *in vivo* study with MR and magnetization transfer. *AJNR Am. J. Neuroradiol.* **16**, 225-231.
- Farooqui, A.A., Rapoport, S.I., and Horrocks, L.A. (1997). Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. *Neurochem. Res.* **22**, 523-527.
- Farooqui, A.A., Yang, H.C., Hirashima, Y., and Horrocks, L.A. (1999). Determination of plasmalogen-selective phospholipase A2 activity by radiochemical and fluorometric assay procedures. *Methods Mol. Biol.* **109**, 39-47.
- Farooqui, A.A., Ong, W.Y., and Horrocks, L.A. (2006). Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. *Pharmacol. Rev.* **58**, 591-620.
- Green, J.T., Orr, S.K., and Bazinet, R.P. (2008). The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. *J. Lipid Res.* **49**, 939-944.
- Hazen, S.L., and Gross, R.W. (1991). ATP-dependent regulation of rabbit myocardial cytosolic calcium-independent phospholipase A2. *J. Biol. Chem.* **266**, 14526-14534.
- Hazen, S.L., Stuppy, R.J., and Gross, R.W. (1990). Purification and characterization of canine myocardial cytosolic phospholipase A2. A calcium-independent phospholipase with absolute f1-2 regioselectivity for diradyl glycerophospholipids. *J. Biol. Chem.* **265**, 10622-10630.
- Hiraoka, M., Abe, A., and Shayman, J.A. (2002). Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. *J. Biol. Chem.* **277**, 10090-10099.
- Hooks, S.B., and Cummings, B.S. (2008). Role of Ca2+-independent phospholipase A2 in cell growth and signaling. *Biochem. Pharmacol.* **76**, 1059-1067.
- Junqueira, R., Cordeiro, Q., Meira-Lima, I., Gattaz, W.F., and Valada, H. (2004). Allelic association analysis of phospholipase A2 genes with schizophrenia. *Psychiatry Genet.* **14**, 157-160.
- Kalyvas, A., and David, S. (2004). Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. *Neuron* **41**, 323-335.
- Kalyvas, A., Baskakis, C., Magrioti, V., Constantinou-Kokotou, V., Stephens, D., Lopez-Vales, R., Lu, J.Q., Yong, V.W., Dennis, E.A., Kokotos, G., et al. (2009). Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. *Brain* **132**, 1221-1235.
- Kim, D.K., and Bonventre, J.V. (1993). Purification of a 100 kDa phospholipase A2 from spleen, lung and kidney: antiserum raised to pig spleen phospholipase A2 recognizes a similar form in bovine lung, kidney and platelets, and immunoprecipitates phospholipase A2 activity. *Biochem. J.* **294** (Pt 1), 261-270.
- Klivenyi, P., Beal, M.F., Ferrante, R.J., Andreassen, O.A., Wermer, M., Chin, M.R., and Bonventre, J.V. (1998). Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. *J. Neurochem.* **71**, 2634-2637.
- Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
- Larsson, P.K., Claesson, H.E., and Kennedy, B.P. (1998). Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. *J. Biol. Chem.* **273**, 207-214.
- Lio, Y.C., and Dennis, E.A. (1998). Interfacial activation, lysophospholipase and transacylase activity of group VI Ca2+-independent phospholipase A2. *Biochim. Biophys. Acta* **1392**, 320-332.
- Lucas, K.K., and Dennis, E.A. (2005). Distinguishing phospholipase A2 types in biological samples by employing group-specific assays in the presence of inhibitors. *Prostaglandins Other Lipid Mediat.* **77**, 235-248.
- Lukacova, N., Halat, G., Chavko, M., and Marsala, J. (1996). Ischemia-reperfusion injury in the spinal cord of rabbits strongly enhances lipid peroxidation and modifies phospholipid profiles. *Neurochem. Res.* **21**, 869-873.
- Molloy, G.Y., Rattray, M., and Williams, R.J. (1998). Genes encoding multiple forms of phospholipase A2 are expressed in rat brain. *Neurosci. Lett.* **258**, 139-142.
- Pickard, R.T., Striffler, B.A., Kramer, R.M., and Sharp, J.D. (1999). Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2. *J. Biol. Chem.* **274**, 8823-8831.
- Pinto, F., Brenner, T., Dan, P., Krimsky, M., and Yedgar, S. (2003). Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. *Glia* **44**, 275-282.
- Ramanadham, S., Wolf, M.J., Ma, Z., Li, B., Wang, J., Gross, R.W., and Turk, J. (1996). Evidence for association of an ATP-stimulatable Ca(2+)-independent phospholipase A2 from pancreatic islets and HIT insulinoma cells with a phosphofructokinase-like protein. *Biochemistry* **35**, 5464-5471.
- Riendeau, D., Guay, J., Weech, P.K., Laliberte, F., Yergey, J., Li, C., Desmarais, S., Perrier, H., Liu, S., Nicoll-Griffith, D., et al. (1994). Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyicosatetraenoic acid by calcium ionophore-challenged platelets. *J. Biol. Chem.* **269**, 15619-15624.
- Ross, B.M., Hudson, C., Erlich, J., Warsh, J.J., and Kish, S.J. (1997). Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. *Arch. Gen. Psychiatry* **54**, 487-494.
- Ross, B.M., Turenne, S., Moszczynska, A., Warsh, J.J., and Kish, S.J. (1999). Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. *Brain Res.* **821**, 407-413.
- Schaloske, R.H., and Dennis, E.A. (2006). The phospholipase A2 superfamily and its group numbering system. *Biochim. Biophys. Acta* **1761**, 1246-1259.
- Scheler, C., Lamer, S., Pan, Z., Li, X. P., Salnikow, J., and Jungblut, P. (1998). Peptide mass fingerprint sequence coverage from differently stained proteins on two-dimensional electrophoresis patterns by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS). *Electrophoresis* **19**, 918-927.
- Shinzawa, K., Sumi, H., Ikawa, M., Matsuoka, Y., Okabe, M., Sakoda, S., and Tsujimoto, Y. (2008). Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. *J. Neurosci.* **28**, 2212-2220.
- Stephenson, D.T., Lemere, C.A., Selkoe, D.J., and Clemens, J.A. (1996). Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. *Neurobiol. Dis.* **3**, 51-63.
- Street, I.P., Lin, H.K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier, H., Tremblay, N.M., Huang, Z., Weech, P.K., and Gelb, M.H. (1993). Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. *Biochemistry* **32**, 5935-5940.
- Strokin, M., Sergeeva, M., and Reiser, G. (2007). Prostaglandin

- synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2. *J. Neurochem.* 102, 1771-1782.
- Sun, G.Y., Xu, J., Jensen, M.D., and Simonyi, A. (2004). Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. *J. Lipid Res.* 45, 205-213.
- Sun, G.Y., Shelat, P.B., Jensen, M.B., He, Y., Sun, A.Y., and Simonyi, A. (2010). Phospholipases A2 and inflammatory responses in the central nervous system. *Neuromol. Med.* 12, 133-148.
- Tabuchi, S., Uozumi, N., Ishii, S., Shimizu, Y., Watanabe, T., and Shimizu, T. (2003). Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury. *Acta Neurochir. Suppl* 86, 169-172.
- Takemiya, T., Matsumura, K., and Yamagata, K. (2007). Roles of prostaglandin synthesis in excitotoxic brain diseases. *Neurochem. Int.* 51, 112-120.
- Tang, J., Kriz, R.W., Wolfman, N., Shaffer, M., Seehra, J., and Jones, S.S. (1997). A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. *J. Biol. Chem.* 272, 8567-8575.
- Tariq, M., Khan, H.A., Al Moutaery, K., and Al Deeb, S. (2001). Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. *Brain Res. Bull.* 54, 77-82.
- Trimble, L.A., Street, I.P., Perrier, H., Tremblay, N.M., Weech, P.K., and Bernstein, M.A. (1993). NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-kDa human phospholipase A2. *Biochemistry* 32, 12560-12565.
- Ushakova, A.V., Grivennikova, V.G., Ohnishi, T., and Vinogradov, A.D. (1999). Triton X-100 as a specific inhibitor of the mammalian NADH-ubiquinone oxidoreductase (Complex I). *Biochim. Biophys. Acta* 1409, 143-153.
- Wolf, R.A., and Gross, R.W. (1985). Identification of neutral active phospholipase C which hydrolyzes choline glycerophospholipids and plasmalogen selective phospholipase A2 in canine myocardium. *J. Biol. Chem.* 260, 7295-7303.
- Yao, J.K., Leonard, S., and Reddy, R.D. (2000). Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. *Schizophr. Res.* 42, 7-17.
- Yoshinaga, N., Yasuda, Y., Murayama, T., and Nomura, Y. (2000). Possible involvement of cytosolic phospholipase A(2) in cell death induced by 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in GH3 cells. *Brain Res.* 855, 244-251.